ERCC1 and breast carcinoma: In 2015, Dumont and his colleagues proposed that the genotypes of ERCC1 rs11615 and CYP1B1 rs1056836 can jointly predict the prognosis responses to neoadjuvant chemotherapy of breast cancer patients, especially ER positive ones [50].